Cardiff Oncology finalizes separation agreements with ex-CEO and ex-CFO

Cardiff Oncology, Inc.

Dr. Erlander to receive $635k salary over 12 months, $122k 2025 bonus, and 50% of 2026 target bonus pro-rated.
Mr. Levine to receive $490k salary over 12 months, $61.7k 2025 bonus, and 50% of 2026 target bonus pro-rated.
Erlander signs consulting agreement; stock options vest through June 2026, then exercisable for 12 months.
Levine's vested options exercisable for 12 months after separation date.
Erlander resigns from board of directors effective March 27, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.